Table 2.
Urine hrHPV and hrHPV genotype detection compared to cervical samples.
| Groups compared | Urine samples |
Cervical samples |
Prevalence % (95% CI) | Sensitivity % (95% CI) | Specificity % (95% CI) | PPV % (95% CI) | NPV % (95% CI) | McNemar p-value | Overall percent agreement | Positive percent agreement | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| hrHPV positive | hrHPV negative | |||||||||||
| 1, 2, 3 | Urine hrHPV detection (compared to cervical hrHPV detection) | hrHPV positive | 39 | 2 | 65.6 (58.3–72.2) |
31.5 (23.6–40.5) |
96.9 (88.3–99.5) |
95.1 (82.2–99.2) |
42.6 (34.6–51.0) |
<0.001 | 54.0% | 31.5% |
| hrHPV negative | 85 | 63 | ||||||||||
| hrHPV 16 or 18/45 positive | hrHPV 16 or 18/45 negative | |||||||||||
| 1,2 # | Urine hrHPV genotyping (compared to cervical hrHPV genotyping) | hrHPV 16 or 18/45 positive | 4 | 0 | 35.1 (23.2–48.9) |
20.0 (6.6–44.3) |
100 (88.3–100.0) |
100 (39.6–100.0) |
69.8 (55.5–81.3) |
<0.001 | 71.9% | 20.0% |
| hrHPV 16 or 18/45 negative | 16 | 37 | ||||||||||
# (57 patients had concurrent genotyping at time of pap smear collection); hrHPV: high-risk human papillomavirus; PPV: Positive predictive value; NPV: Negative predictive value; CI: Confidence interval.